Save this technology
close
Save to Existing Project
Save to a New Project
Novel Target Anti-lung Cancer SiRNA Therapies, Treatment Drugs
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Neomics has found a very promising target, AIMP2/AIMP2-DX2 for siRNA therapy application to tumoric lung cancer cells and we intend to focus the remaining resources on developing through clinical trials, the siRNA therapy as a first priority
Contact Yong U Kim
RE:
Participants
You

. Unique Merits of AIMP2 Targeting Anticancer Drugs


1.     Previously Unexplored Target with Novel Working Mechanisms


             (Global Initiatives in R&D and IP Position)


2.     Generation of Tumorigenic Variant of AIMP2 Is  Major Cause for Lung Caner


(Cancer-specific Target Available)


3.     Suppression of AIMP2-DX2 Proven Effective against Lung Cancer


4.     Small Chemical and siRNA Drug Candidates Are Available


5.     Patents for Material and Usage Are Established Worldwide


. Our Products to develop


•      Si-DX2 therapy -


–      Specific AIMP2-DX2 inhibitor


–      Aerosol inhalation administration


–      Low toxicity and high efficiency of delivery


•      Diagnostics


–      Immuno histochemical Method


–      QPCR AIMP2DX2 detection


–      RISH detection system


–      AIMP2 targeting small chemical drugs


–      4 drug candidates identified


Animal efficacy show


 

Type of Business Relationship Sought
1. Overseas Licensing Opportunity 2. Seeking potential corporate partners
FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
GOVERNMENT INSTITUTE

Opportunity Contact